Arjuna Therapeutics Overview
- Founded
- 2006
- Status
- Private
- Employees
- 8
- Latest Deal Type
- Later Stage VC
- Investors
- 6
Arjuna Therapeutics General Information
Description
Developer of an entirely novel class of orally available small molecules intended to address untreatable cancers. The company's nanomaterials aim to redefine the treatment landscape for solid tumors on both sides of the blood-brain barrier by targeting all cancers that generate high levels of Reactive Oxygen Species, enabling to revolutionize cancer treatment for patients and their doctors.
Contact Information
Website
www.arjunatherapeutics.com
Formerly Known As
NANOGAP
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Polig. Ind. Novo Milladoiro C / Xesta
- Nº 78A, Milladoiro
- 15895 A Coruna
- Spain
Arjuna Therapeutics Timeline
Arjuna Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 20-Dec-2019 | 00.000 | Completed | Pre-Clinical Trials | ||
| 5. Later Stage VC | 11-Jan-2019 | 00.000 | 00.000 | 000.00 | Completed | Pre-Clinical Trials |
| 4. Grant | 20-Jan-2016 | 000.00 | 00.000 | Completed | Pre-Clinical Trials | |
| 3. Later Stage VC | 23-Sep-2014 | 00.000 | 00.000 | 000.00 | Completed | Pre-Clinical Trials |
| 2. Later Stage VC | 16-Mar-2012 | Completed | Pre-Clinical Trials | |||
| 1. Grant | 01-Jan-2011 | Completed | Startup |
Arjuna Therapeutics Patents
Arjuna Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3819018-A1 | Forward osmosis draw solute | Pending | 08-Nov-2019 | 0000000000 | 0 |
| US-20200368657-A1 | Filtration device comprising atomic quantum clusters | Pending | 10-May-2019 | 000000000 | |
| AU-2019349780-A1 | Therapeutic uses of atomic quantum clusters | Pending | 26-Sep-2018 | 000000000 | |
| CA-3111915-A1 | Therapeutic uses of atomic quantum clusters | Pending | 26-Sep-2018 | 000000000 | |
| EP-3862109-A2 | Therapeutic uses of atomic quantum clusters | Pending | 26-Sep-2018 | A61K33/38 |
Arjuna Therapeutics Executive Team (9)
Arjuna Therapeutics Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Charlie Sheppard | Arjuna Therapeutics | Co-Founder, Chief Commercial Officer and Board Member | 000 0000 |
| Darren Bianchi | Arjuna Therapeutics | Co-Founder and Board Member | 000 0000 |
| Graeme Martin Ph.D | Self | Board Member | 000 0000 |
| Ross Breckenridge Ph.D | Arjuna Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
| Tatiana López | Arjuna Therapeutics | Board Member | 000 0000 |
Arjuna Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialArjuna Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Repsol Corporate Venturing | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Horizon 2020 SME Instrument | Government | 000 0000 | 000000 0 | ||
| Caixa Capital Risc | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Uninvest | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Unirisco Galicia | Venture Capital | Minority | 000 0000 | 000000 0 |